Boehringer Ingelheim is enrolling patients with inoperable malignant pleural mesothelioma (MPM) into a Phase 2/3 trial evaluating the effectiveness of nintedanib in combination with Alimta (pemetrexed) and Platinol (cisplatin), followed by ... Read more